CD34 Selection Using the Automated CliniMACS Prodigy
Conditions: AML; ALL; Lymphoid Malignancies; Myelodysplastic Syndromes; CML; Primary Myelofibrosis Intervention: Drug: Infusion of CD34 selected hematopoietic stem cells Sponsor: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Condition: Multiple Myeloma Interventions: Biological: idecabtagene vicleucel; Drug: Lenalidomide; Drug: Fludarabine; Drug: Cyclophosphamide Sponsor: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
CD34 Selection Using the Automated CliniMACS Prodigy
Conditions: AML; ALL; Lymphoid Malignancies; Myelodysplastic Syndromes; CML; Primary Myelofibrosis Intervention: Drug: Infusion of CD34 selected hematopoietic stem cells Sponsor: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Condition: Multiple Myeloma Interventions: Biological: idecabtagene vicleucel; Drug: Lenalidomide; Drug: Fludarabine; Drug: Cyclophosphamide Sponsor: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
CD34 Selection Using the Automated CliniMACS Prodigy
Conditions: AML; ALL; Lymphoid Malignancies; Myelodysplastic Syndromes; CML; Primary Myelofibrosis Intervention: Drug: Infusion of CD34 selected hematopoietic stem cells Sponsor: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Condition: Multiple Myeloma Interventions: Biological: idecabtagene vicleucel; Drug: Lenalidomide; Drug: Fludarabine; Drug: Cyclophosphamide Sponsor: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
CD34 Selection Using the Automated CliniMACS Prodigy
Conditions: AML; ALL; Lymphoid Malignancies; Myelodysplastic Syndromes; CML; Primary Myelofibrosis Intervention: Drug: Infusion of CD34 selected hematopoietic stem cells Sponsor: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Condition: Multiple Myeloma Interventions: Biological: idecabtagene vicleucel; Drug: Lenalidomide; Drug: Fludarabine; Drug: Cyclophosphamide Sponsor: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
CD34 Selection Using the Automated CliniMACS Prodigy
Conditions: AML; ALL; Lymphoid Malignancies; Myelodysplastic Syndromes; CML; Primary Myelofibrosis Intervention: Drug: Infusion of CD34 selected hematopoietic stem cells Sponsor: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Condition: Multiple Myeloma Interventions: Biological: idecabtagene vicleucel; Drug: Lenalidomide; Drug: Fludarabine; Drug: Cyclophosphamide Sponsor: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
CD34 Selection Using the Automated CliniMACS Prodigy
Conditions: AML; ALL; Lymphoid Malignancies; Myelodysplastic Syndromes; CML; Primary Myelofibrosis Intervention: Drug: Infusion of CD34 selected hematopoietic stem cells Sponsor: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Conditions: Multiple Myeloma Interventions: Biological: idecabtagene vicleucel; Drug: Lenalidomide; Drug: Fludarabine; Drug: Cyclophosphamide Sponsors: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
CD34 Selection Using the Automated CliniMACS Prodigy
Conditions: AML; ALL; Lymphoid Malignancies; Myelodysplastic Syndromes; CML; Primary Myelofibrosis Interventions: Drug: Infusion of CD34 selected hematopoietic stem cells Sponsors: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
